COVID-19 patients experiencing headache symptoms exhibited elevated concentrations of inflammatory molecules and harmful molecules (high-mobility group protein B1 (HMGB1), NOD-like receptor thermal protein domain-associated protein 3 (NLRP3), and IL-6), potentially contributing to the initiation of trigeminal activation [220,221]. The gene discussed is HMGB1; the disease is COVID-19.